124029
Akt Inhibitor XII, Isozyme-Selective, Akti-2
The Akt Inhibitor XII, Isozyme-Selective, Akti-2 controls the biological activity of Akt. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
别名:
Akt Inhibitor XII, Isozyme-Selective, Akti-2, 1-((2-(4-((4-(2,3-Dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl)phenyl)-3-phenyl-6-quinoxalinyl)carbonyl)-4-methyl-piperazine, 3HCl and, 1-((3-(4-((4-(2,3-Dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl)methyl)phenyl)-2-phenyl-6-quinoxalinyl
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C39H39N7O2 · 3HCl
分子量:
747.16
UNSPSC代码:
12352200
NACRES:
NA.77
推荐产品
质量水平
方案
≥97% (mixture of regioisomers, HPLC)
表单
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
desiccated (hygroscopic)
protect from light
颜色
yellow
溶解性
DMSO: 25 mg/mL
water: 50 mg/mL
运输
ambient
储存温度
2-8°C
一般描述
A cell-permeable Akti-1/2- (Cat. No. 124018) derived allosteric inhibitor pair (1:1 regioisomeric mixture) with much improved aqueous solubility (10 mg/ml in a pH 7.4 saline) and Akt2 selectivity (IC50 = 805 nM for Akt2, >10 µM for Akt1/3, and >50 µM for PKA/PKC/SGK). The inhibition is PH domain-dependent and non-competitive with ATP.
A cell-permeable Akti-1/2- (Cat. No. 124018) derived allosteric inhibitor pair (1:1 regioisomeric mixture) with much improved aqueous solubility (10 mg/ml in a pH 7.4 saline) and Akt2 selectivity (IC50 = 805 nM for Akt2, >10 µM for Akt1/3, and >50 µM for PKA/PKC/SGK). The inhibition is PH domain-dependent and non-competitive with ATP.
包装
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Kenneth K Y Ting et al.
ImmunoHorizons, 8(1), 57-73 (2024-01-09)
The accumulation of lipid and the formation of macrophage foam cells is a hallmark of atherosclerosis, a chronic inflammatory disease. To better understand the role of macrophage lipid accumulation in inflammation during atherogenesis, we studied early molecular events that follow
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门